New study characterizes protein’s role in regulating DNA replication in human cancer cells

Center for Cancer Research investigators have found that the RepID protein recruits the CRL4 protein complex to chromatin early in the cell cycle, playing a critical role in regulating DNA replication. The findings suggest possible therapeutic targets to tighten the reigns on DNA replication. Read more...

immunotherapy research

New clinical trial tests prime-and-boost vaccine delivery for advanced solid tumors

Apr 3, 2018

Researchers are testing a prime-and-boost approach to safely direct the immune system to kill tumor cells that express brachyury, a protein expressed in high levels in some cancers. A new clinical trial is testing an experimental vaccine in patients whose cancers have not responded to standard treatments. Read more...

CCR scientists to present at 2018 AACR Annual Meeting in Chicago

Apr 2, 2018

The Annual Meeting of the American Association for Cancer Research (AACR) covers the latest basic, translational, clinical and prevention-focused cancer research in the field. The 2018 AACR Annual Meeting —“Driving Innovative Cancer Science to Patient Care” — will take place on April 14-18 in Chicago and feature presentations from several CCR scientists. View the list of CCR presentations at AACR…

CCR scientists to present at 2018 AACR Annual Meeting in Chicago
stethoscope

CCR celebrates Doctors Day

Mar 30, 2018

March 30th marks the annual observation of National Doctors Day.  Learn more...

merkel cell carcinoma

International Workshop on Merkel Cell Carcinoma Research (IWMCC) held in early March

Mar 29, 2018

Over 50 global thought-leaders gathered in early March to discuss and identify the most important research questions in Merkel cell carcinoma (MCC). Read more...

Skin lesion of lupus patient

New study shows normally helpful natural bacteria may also trigger lupus

Mar 28, 2018

CCR scientists have discovered that a protein produced by bacteria that naturally inhabit our bodies may trigger the autoimmune disease lupus. The results of the study could unveil an entirely new set of drug targets for treating lupus and other autoimmune diseases. Read more…

Christian Hinrichs and Arrica Wallace

CCR clinical trial patients featured in AFP article

Mar 28, 2018

A clinical trial at the National Cancer Institute led by Christian Hinrichs, M.D., Investigator in the Experimental Transplantation and Immunology Branch, offered the first evidence in support of immunotherapy as an effective treatment for cervical cancer. In a recent article, Agence France Presse highlights the journeys of Sue Scott and Arrica Wallace, two women on the trial for whom the experimental cancer treatment worked. Read the full article…

CCR clinical trial patients featured in AFP article
Christian Hinrichs

AFP article profiles CCR’s Christian Hinrichs, a cancer survivor now leading clinical trials

Mar 27, 2018

In 2005, Christian Hinrichs, M.D., Investigator in the Experimental Transplantation and Immunology Branch, underwent surgery to remove his right eye due to a rare cancer called ocular melanoma. The operation affected his depth perception and ended his career as a cancer surgeon, but Dr. Hinrichs was determined to find a way to beat the cancer and went back to school to train as an internal medicine doctor and oncologist. In a recent article from Agence France Presse, he describes how his diagnosis now drives his quest for a cancer cure. Read the full story…

AFP article profiles CCR’s Christian Hinrichs, a cancer survivor now leading clinical trials
Milestones cover

CCR’s 2017-18 Milestones publication is now available

Mar 26, 2018

Every year, the Center for Cancer Research makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. The CCR’s annual publication, Milestones, features select research highlights from the past year to illustrate the quality and spectrum of our work in the basic and clinical sciences. Read the 2017-18 issue of Milestones…

CCR’s 2017-18 Milestones publication is now available
Richard Mulcahy

Defeating a rare, aggressive form of skin cancer with avelumab

Mar 23, 2018

For the one-year anniversary of the FDA’s approval of avelumab, CCR Communications caught up with Richard Mulcahy to share his success story as a clinical trial patient. Mulcahy was diagnosed with Merkel cell carcinoma in September of 2016. It’s been over a year since he received his first treatment of avelumab as part of a clinical trial led by Isaac Brownell, M.D., Ph.D., formerly an Investigator in the Dermatology Branch, at the National Cancer Institute (NCI) in Bethesda. Read more...

Lymphoma cells

Clinical trial uses combination therapy for certain types of non-Hodgkin lymphoma

Mar 22, 2018

Researchers are testing the safety of the combination of an experimental drug with rituximab, a standard treatment, for patients with indolent or diffuse large B-cell lymphoma. The antibody is designed to target and block a protein that is present on cancer cells and is used by those cells to protect themselves from your body’s immune system. Blocking the protein may enable your body’s immune system to find and destroy the cancer cells. Read more…

Pages